What is Elmedix?
Elmedix, founded in 2015 as a spin-off from the University of Antwerp, is pioneering a novel therapeutic approach to combat challenging tumors, including pancreatic cancer. The company's technology platform precisely elevates a patient's body temperature, a method designed to increase the sensitivity of cancer cells to conventional chemotherapy and radiotherapy. This synergistic treatment strategy aims to significantly improve patient outcomes. Clinical trials are currently underway in collaboration with UZ Antwerpen to validate the safety and effectiveness of this groundbreaking treatment.
How much funding has Elmedix raised?
Elmedix has raised a total of $4.5M across 1 funding round:
Unspecified
$4.5M
Unspecified (2022): $4.5M, investors not publicly disclosed
What's next for Elmedix?
The recent major strategic investment signals a critical growth phase for Elmedix, likely enabling the company to advance its clinical trials, scale its operations, and potentially prepare for broader market entry. This enterprise-level funding suggests confidence from investors in Elmedix's unique technology and its potential to disrupt current cancer treatment paradigms. The company is poised to leverage this capital to further validate its platform and move towards commercialization, aiming to make its temperature-elevation therapy a standard adjunct in oncology.
See full Elmedix company page
